Suspect charged after Vancouver car ramming leaves 11 dead    Suspect in killing of general claims he was paid by Ukraine    North Korea confirms troop deployment to Russia for first time    Makkah police arrest Yemeni and Egyptian suspects of fake Hajj campaign    400-800 year old giant coral colony discovered within AMAALA waters in the Red Sea    HR Ministry launches 'Ajeer Al-Hajj' service for seasonal work during Hajj 2025    Kafalah grants 1,900 loan guarantees worth over SR4.8 billion to SMEs during 1Q 2025    Council of Senior Scholars reaffirms performing Hajj without a permit is a sinful act    King and Crown Prince offer condolence to Iranian president over the deadly port explosion    stc reports strong first-quarter 2025 results with 11% rise in net profit    Virgin Atlantic celebrates one month of nonstop service between London and Riyadh    Saudi Awwal Bank records SR2.1 billion net profit after zakat and income tax for 1Q25    Duran leads Al Nassr past Yokohama Marinos into AFC Champions League Elite semi-finals    Al Ahli cruise past Buriram into AFC Champions League Elite semi-finals    Saudi orchestra to perform at Sydney Opera House in May    Al Hilal thrash Gwangju to reach AFC Champions League Elite semi-finals    Saudi Theater Commission launches its Work and Learn Project in UK    The season has begun — and one comment shook us all    Average life expectancy in Saudi Arabia rises to78.8 years    Famed Philippine film star Nora Aunor dies at 71    Pakistani star's Bollywood return excites fans and riles far right    Veteran Bollywood actor Manoj Kumar dies at 87    Bollywood actress vindicated over boyfriend's death after media hounding    Grand Mufti rules against posting prayers and preaching in mosques on social media    Exotic Taif Roses Simulation Performed at Taif Rose Festival    Asian shares mixed Tuesday    Weather Forecast for Tuesday    Saudi Tourism Authority Participates in Arabian Travel Market Exhibition in Dubai    Minister of Industry Announces 50 Investment Opportunities Worth over SAR 96 Billion in Machinery, Equipment Sector    HRH Crown Prince Offers Condolences to Crown Prince of Kuwait on Death of Sheikh Fawaz Salman Abdullah Al-Ali Al-Malek Al-Sabah    HRH Crown Prince Congratulates Santiago Peña on Winning Presidential Election in Paraguay    SDAIA Launches 1st Phase of 'Elevate Program' to Train 1,000 Women on Data, AI    41 Saudi Citizens and 171 Others from Brotherly and Friendly Countries Arrive in Saudi Arabia from Sudan    Saudi Arabia Hosts 1st Meeting of Arab Authorities Controlling Medicines    General Directorate of Narcotics Control Foils Attempt to Smuggle over 5 Million Amphetamine Pills    NAVI Javelins Crowned as Champions of Women's Counter-Strike: Global Offensive (CS:GO) Competitions    Saudi Karate Team Wins Four Medals in World Youth League Championship    Third Edition of FIFA Forward Program Kicks off in Riyadh    Evacuated from Sudan, 187 Nationals from Several Countries Arrive in Jeddah    SPA Documents Thajjud Prayer at Prophet's Mosque in Madinah    SFDA Recommends to Test Blood Sugar at Home Two or Three Hours after Meals    SFDA Offers Various Recommendations for Safe Food Frying    SFDA Provides Five Tips for Using Home Blood Pressure Monitor    SFDA: Instant Soup Contains Large Amounts of Salt    Mawani: New shipping service to connect Jubail Commercial Port to 11 global ports    Custodian of the Two Holy Mosques Delivers Speech to Pilgrims, Citizens, Residents and Muslims around the World    Sheikh Al-Issa in Arafah's Sermon: Allaah Blessed You by Making It Easy for You to Carry out This Obligation. Thus, Ensure Following the Guidance of Your Prophet    Custodian of the Two Holy Mosques addresses citizens and all Muslims on the occasion of the Holy month of Ramadan    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Pfizer doubling patient income limit for free drug program
Published in Saudi Press Agency on 06 - 11 - 2015

As the furor over soaring U.S. prescription drug prices escalates and outrageous price hikes by several smaller drugmakers give the entire industry a black eye, the biggest U.S.-based drugmaker is expanding financial assistance to patients, according to AP.
Pfizer Inc. said Thursday that it's doubling the allowable income level for people to receive dozens of its medicines without a copayment because more patients are in need. Patients' insurance plans generally must pay the bulk of the drug's cost. Some critics say this isn't the best way to keep drugs affordable for everyone.
"It's not addressing the price of the drug," said Clare Krusing, a spokesperson for the trade group America's Health Insurance Plans.
"This is the wrong approach when you consider the cost impact that patients have on the back end," because insurance plans eventually raise patients' monthly premiums to compensate, said Krusing.
She added that widely used drugmaker coupon programs, which either cover patient copayments for a specific brand-name drug or limit the copayments to a small amount, usually are temporary, lasting a year or so.
Insurers and other critics say such programs increase overall health spending, particularly ones that nudge patients to stay on brand-name drugs when cheaper generic versions are available.
New medicines for cancer, hepatitis C and rare diseases carry list prices of $100,000 or more for a year or a course of treatment, though insurers often get big discounts. Meanwhile, insurance plans increasingly require patients to pay a large percentage of the price for the costliest drugs, rather than a fixed monthly amount.
The move comes amid fierce criticism by patients and politicians, as well as a growing number of government investigations, of six-figure prices for new medications and huge price hikes on old ones with little or no competition â€" up to 5,000 percent, for a drug for a life-threatening parasitic infection now sold by Turing Pharmaceuticals.
Turing, Valeant Pharmaceuticals International Inc. and a handful of other companies have been accused of price gouging. Meanwhile, a continuing wave of mergers of both brand-name and generic drug manufacturers threatens to further limit competition, the primary control on prices in the U.S.
Pharmaceuticals analyst Erik Gordon, a professor at University of Michigan's Ross School of Business, said drugmakers face "a wave of hearings and public beatings" over exorbitant drug prices.
"If you're Pfizer, you want to look like you've made a voluntary, charitable move before you get beat up" in a congressional hearing, Gordon said.
Most drugmakers offer financial assistance to patients, particularly when pricey new drugs are first launched and the companies are trying to get patients to start taking them, so they can recoup their $1 billion-plus in development costs.
The industry's 20-year-old Partnership for Prescription Assistance connects patients to about 475 assistance programs, nearly 20 of them run by drugmakers.
Pfizer Chief Executive Ian Read told The Associated Press in an exclusive interview that the New York company isn't boosting assistance due to the heightened scrutiny of prices, but because more and more patients can't afford needed medicines.
Read, the immediate past board chairman of industry trade group Pharmaceutical Research and Manufacturers of America, said Pfizer is "responding to challenges patients are having."
He cited insurance plans that now shift more costs onto patients through higher medication copayments and deductibles that must be met before coverage kicks in, plus some Affordable Care Act exchange plans and insurance formularies that exclude pricier prescription drugs.
"There are people who are falling through the cracks through no fault of their own," Read said. "As a stopgap, we're willing to do this."
Under the Pfizer RxPathways program, the company will cover patient copayments for 44 medicines for both uninsured and underinsured patients earning up to four times the federal poverty level, up from twice that level. The new limits are $47,080 annually for a single person and $97,000 for a family of four.
The program covers many popular Pfizer brands: pain relievers Celebrex and Lyrica, smoking cessation aids Chantix and Nicotrol, the Prevnar 13 pneumococcal vaccine and erectile dysfunction pill Viagra. Nearly 20 additional Pfizer medicines, including numerous expensive cancer drugs, already were free to patients making up to four times the poverty level.
Last year, the RxPathways program helped about 350,000 patients. Pfizer expects to help a few hundred thousand more than that next year. Between 2010 and 2014, the program helped nearly 2.5 million people get more than 30 million Pfizer prescriptions worth more than $7 billion at list prices.
There's no sign other drugmakers are expanding their assistance programs, and Gilead Sciences Inc., maker of new hepatitis C medicines with list prices of around $90,000 for a course of treatment, recently decreased the number of patients it is helping, forcing more costs onto insurers.
Merck & Co., the second-biggest U.S. drugmaker by revenue, since 2010 has offered assistance to patients with incomes up to five times the federal poverty level for some of its most-expensive medicines and four times that level for the rest.
Asked why Pfizer doesn't just reduce list prices for its drugs in the U.S., where medicines generally cost a few times more than in other wealthy countries, Read said high prices are needed to fund innovative research on future drugs. That's long been the industry's mantra.
"Our prices, we think, are appropriate," Read said. "We can't lower the prices enough for (many patients) to afford it."


Clic here to read the story from its source.